Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.
Profitability
This table compares Vivos Therapeutics and Intelligent Bio Solutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| Intelligent Bio Solutions | -294.88% | -175.35% | -91.25% |
Valuation and Earnings
This table compares Vivos Therapeutics and Intelligent Bio Solutions”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $20.90 million | 0.06 | -$21.17 million | ($1.90) | -0.05 |
| Intelligent Bio Solutions | $4.22 million | 1.78 | -$12.43 million | ($9.02) | -0.25 |
Intelligent Bio Solutions has lower revenue, but higher earnings than Vivos Therapeutics. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Vivos Therapeutics has a beta of 6.37, indicating that its share price is 537% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.48, indicating that its share price is 348% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations for Vivos Therapeutics and Intelligent Bio Solutions, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Intelligent Bio Solutions | 1 | 1 | 0 | 0 | 1.50 |
Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 2,804.56%. Given Vivos Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Vivos Therapeutics is more favorable than Intelligent Bio Solutions.
Summary
Vivos Therapeutics beats Intelligent Bio Solutions on 9 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
